ArticleNeurology and therapy2026
Real-World, Long-Term Outcomes with Cladribine Tablets Versus Other Oral Treatments Among Patients with Multiple Sclerosis.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionMultiple sclerosis (MS) is a demyelinating disease of the central nervous system, often associated with significant disability. As treatment options increase, comparative effectiveness data for disease-modifying therapies (DMTs) are essential. This study evaluated treatment switching, healthcare resource utilization, and cost outcomes among US patients with MS (PwMS) treated with cladribine tablets (CladT) vs. fingolimod (FTY), dimethyl fumarate (DMF), and teriflunomide (TER) during a 4-year follow-up period.
methodsThis retrospective study used claims data from the Komodo Healthcare Map (4/1/2018-3/31/2024). Adult PwMS with ≥ 1 claim for CladT, FTY, DMF, and TER were included. Index date was the first claim date for the respective DMT. Continuous enrollment for 12 months pre-index and 48 months post-index was required. Cohorts were balanced using propensity score weighting and 4-year outcomes were assessed using generalized linear and Cox proportional hazards models.
resultsOverall, 3038 PwMS were included: CladT (n = 140), FTY (n = 454), DMF (n = 1465), and TER (n = 979). In the weighted cohorts, mean age was 48 years, and 74-77% were female. Treatment switching during a 4-year follow-up period was lower for CladT (11%), vs. FTY (42%), DMF (57%), and TER (42%) cohorts. CladT showed lower all-cause medical costs per patient per year (PPPY): $13,377 vs. FTY (adjusted mean difference [AMD] $10,073; 95% confidence interval (CI) $5006-15,148), DMF (AMD $12,013; 95% CI $7490-16,706), and TER (AMD $9917; 95% CI $6558-13,997) cohorts. All-cause total costs PPPY were lower with CladT ($53,007) vs. FTY (AMD $14,140; 95% CI $7181-22,021) and TER (AMD $6652; 95% CI $567-12,395) cohorts, but similar to DMF cohort (AMD $4472; 95% CI - $2011, $11,111).
conclusionPwMS treated with CladT had significantly fewer treatment switches and lower all-cause medical costs vs. FTY, DMF, and TER. Total healthcare costs were lower vs. FTY and TER but similar to DMF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.